153 -4 (66) 2024 - Rakhmanova A.M., Kasimova R.I. - INFORMATIVE VALUE OF CLINICAL AND LABORATORY PARAMETERS IN DIFFERENTIATING PATIENTS WITH CHRONIC HBV BY QUANTITATIVE HBSAG

INFORMATIVE VALUE OF CLINICAL AND LABORATORY PARAMETERS IN DIFFERENTIATING PATIENTS WITH CHRONIC HBV BY QUANTITATIVE HBSAG

Rakhmanova A.M. - Scientific-research Institute of Virology of the Scientific and Applied Medical Center of the Republic of Specialized Epidemiology, Microbiology, Infectious and Parasitic Diseases

DCs Kasimova R.I. - Scientific-research Institute of Virology of the Scientific and Applied Medical Center of the Republic of Specialized Epidemiology, Microbiology, Infectious and Parasitic Diseases

DCs Madraximov Sh.F. - National University of Uzbekistan

DCs Xurramov A.X. - Karshi State University Uzbekistan, Kashkadarya region

PhD Raxmanov M.I. - Scientific-research Institute of Virology of the Scientific and Applied Medical Center of the Republic of Specialized Epidemiology, Microbiology, Infectious and Parasitic Diseases

Resume

In the category of patients with HBsAg less than 1000, the DNA score (0.89) showed a strong correlation. Thus, when analyzing the results, it was found that HBsAg levels were less than 1000 in patients with HBV DNA between 2600 and 8200 copies. Such a strong association was not found with less than 2600 and more than 8200 DNA.

Keywords: Viral hepatitis B, cirrhosis of the liver, qHBsAg, HBV DNA, test stability, liver elastography, ALT, erythrocyte, platelet, segmented neutrophil, monocyte, lymphocytes

First page

840

Last page

845

For citation: Raxmanova A.M., Kasimova R.I., Madraximov Sh.F., Xurramov A.X., Raxmanov M.I. - INFORMATIVE VALUE OF CLINICAL AND LABORATORY PARAMETERS IN DIFFERENTIATING PATIENTS WITH CHRONIC HBV BY QUANTITATIVE HBSAG//New Day in Medicine 4(66)2024 840-845 https://newdayworldmedicine.com/en/article/3758

List of References

1. www.Who.int. Global hepatitis report 2017; 20172. Chu C.M., Liaw Y.F.HBsAg seroclearance in asymptomatic carri-ers of high endemic areas: appreciably high rates during a long-term follow-up Hepatology, 2017;45(2007):1187-11923.
2. Liu C.J., Kao J.H., Chen D.S.Mixed hepatitis B virus genotype infections: the more, the worse? Hepatology, 2006;44:7704.
3. European Association for the Study of the Liver. EASL 2017.
4. Clinical Practice Guidelines on the management of hepatitis B virus infection. //Journal of Hepatology 2017;67:370-3985.
5. Chen, Y. C. Liaw, Y. F. Pharmacotherapeutic options for hepa-titis B. Expert. //Opin. Pharmacother. 2016;6(17):355-367.
6. Kim G. A. et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. //Gut 2014;7(63):1325–1332.
7. Jeng W. J., Chen Y. C., Chien R. N., Sheen I. S. Liaw Y. F. Incidence and predictors of hepatitis B surface antigen sero-clearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen- negative chronic hepatitis B. Hepatology 2018;8(68):425-434.
8. Buti M. et al. Seven- year effi cacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infec-tion. /Dig. Dis. Sci. 2015;9(60):1457-1464.
9. Marcellin P., Lau G.K., Bonino F. et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. //NEngl J Med. 2004;351:1206-12010.
10. Lau G.K.K., Piratvisuth, T., Luo, K.X. et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. //NEngl J Med. 2005;352:2682-2699.

    file

    download